The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,296.00
Bid: 12,322.00
Ask: 12,324.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.016%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,296.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-Australia backs Pfizer virus vaccine over AstraZeneca for under-50s

Thu, 08th Apr 2021 02:20

* Policy shift will hold up vaccination campaign, says PM

* People with first shot should still get their second

* Italy, UK have suggested AstraZeneca shot age limits
(Adds quote from chief health officer, prime minister and adds
detail)

By Colin Packham and Jonathan Barrett

CANBERRA/SYDNEY, April 8 (Reuters) - Australia said on
Thursday it now recommends people under 50 should get Pfizer's
COVID-19 vaccine in preference to AstraZeneca's
shot, a policy shift that it warned would hold up its
inoculation campaign.

The move, a day after European regulators reiterated they
had found possible links between AstraZeneca's shot and reports
of very rare cases of blood clots, is a huge hurdle for
Australia's programme, which had relied on that vaccine.

Australia's Chief Medical Officer, Paul Kelly, told
reporters the risk of clots was extremely low.

"It's only been found in the first dose of the AstraZeneca
vaccine, usually within 4 to 10 days after that vaccine. But it
is serious, and it can cause up to a 25% death rate when it
occurs," he said.

Australia would advise health providers to only give a first
dose of the AstraZeneca vaccine to adults younger than 50 when
the benefit clearly outweighs the risks, he added.

Italy and Britain on Wednesday joined other countries in
suggesting age limits for AstraZeneca's vaccine. But the
European regulators reaffirmed the importance of that shot in
protecting people against COVID-19.

Those who have already had a first AstraZeneca dose without
any serious adverse events "can safely be given their second
dose," Kelly said.

Prime Minister Scott Morrison said the updated advice will
delay Australia's inoculation timetable, but it was too soon to
say when Canberra would now vaccinate its adult population.

"There will be a recalibration of how the programme will
need to be adjusted," Morrison told reporters in Canberra.

Australia has ordered 20 million doses of the Pfizer vaccine
and Morrison said Canberra was in talks to increase the order.

Authorities will continue to give the AstraZeneca vaccine to
people over 70. Those over 50 who opt for the Pfizer vaccine
will have to wait, the government said.

Australia - which had planned to use the AstraZeneca vaccine
for the vast majority of its near 26 million population -
expected to give all adults at least one shot by October.

But its immunisation campaign was already heavily behind
schedule.

It had pledged to administer at least 4 million first doses
by the end of March, but could only deliver 670,000, with the
government blaming the delay on supply issues in Europe.

It had been looking to ramp up the immunisation effort,
underpinned by plans to make 50 million doses of AstraZeneca
vaccine in Australia, produced by CSL Ltd.

Australia began vaccinations much later than some other
nations because of its few infections, which stand at just under
29,400, with 909 deaths, since the pandemic began.

(Global vaccination tracker: https://graphics.reuters.com/world-coronavirus-tracker-and-maps/vaccination-rollout-and-access/)

(Interactive graphic tracking global spread of coronavirus:
https://graphics.reuters.com/world-coronavirus-tracker-and-maps/)

(Reporting by Colin Packham and Jonathan Barrett; Editing by
Michael Perry, Clarence Fernandez and Andrew Heavens)

More News
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more
27 Dec 2023 12:06

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

Read more
27 Dec 2023 11:20

London midday: Stocks ride global wave of post-Christmas optimism

(Sharecast News) - London's equity markets were still above the waterline at lunchtime on Wednesday, following a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:48

LONDON MARKET OPEN: FTSE 100 gains led by miners and industrials

(Alliance News) - Stock prices in London opened in the green on Wednesday, as hopes for US interest rate cuts in the new year continued to propel global equities higher.

Read more
27 Dec 2023 08:26

London open: FTSE takes cues from Wall Street 'Santa rally'

(Sharecast News) - London's stocks returned from the Christmas break in the green on Wednesday, boosted by a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:24

TOP NEWS: AstraZeneca buys Gracell to "enrich" cell therapy pipeline

(Alliance News) - AstraZeneca PLC on Tuesday said it has agreed to acquire Gracell Biotechnologies Inc, paying about USD1.2 billion for the clinical-stage company.

Read more
27 Dec 2023 07:52

LONDON BRIEFING: AstraZeneca buys Gracell Biotech; COPL CEO resigns

(Alliance News) - Stocks in London were expected to make gains at Wednesday's market open, as investors continued to pin their hopes on US interest rate cuts.

Read more
27 Dec 2023 07:02

AstraZeneca to buy Gracell Technologies for $1.2bn

(Sharecast News) - AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.